Erythromycin and bromhexine in acute exacerbations of chronic bronchitis. A study on sputum penetration and clinical effectiveness
- PMID: 6981522
Erythromycin and bromhexine in acute exacerbations of chronic bronchitis. A study on sputum penetration and clinical effectiveness
Abstract
A group of 22 patients with acute purulent exacerbations of chronic bronchitis were treated with 1 g erythromycin ethyl succinate granules twice daily orally for 10 days. Half the patients were given bromhexine additionally and the other half received placebo instead. Serum and sputum erythromycin concentrations were measured microbiologically at intervals after the first dose. The clinical results in both treated groups were rather poor, with many patients becoming infected again immediately after the chemotherapy. Blood and sputum concentrations of erythromycin did not greatly differ in the two patient groups. The sputum concentration of erythromycin was often higher than the blood concentration at the same time. The MIC's of erythromycin (in particular, those for the Haemophilus influenzae strains) were often higher than the drug concentrations attained in the sputum.
Similar articles
-
Twice daily dosage of bacampicillin in chronic bronchitis. A double-blind study.Scand J Respir Dis. 1978 Oct;59(5):249-56. Scand J Respir Dis. 1978. PMID: 32615 Clinical Trial.
-
Influence of a fluidifying agent (bromhexine) on the penetration of antibiotics into respiratory secretions.Int J Clin Pharmacol Res. 1985;5(5):341-4. Int J Clin Pharmacol Res. 1985. PMID: 4066084 Clinical Trial.
-
Bacampicillin twice daily: a dose-response study in acute exacerbations of chronic bronchitis.Eur J Respir Dis. 1981 Dec;62(6):434-40. Eur J Respir Dis. 1981. PMID: 7347694
-
Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.Int J Antimicrob Agents. 2004 Jun;23(6):533-46. doi: 10.1016/j.ijantimicag.2004.02.017. Int J Antimicrob Agents. 2004. PMID: 15194123 Review.
-
[Role of thiamphenicol in the treatment of community-acquired lung infections].Med Trop (Mars). 2004;64(1):33-8. Med Trop (Mars). 2004. PMID: 15224555 Review. French.
Cited by
-
Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis.Eur Respir Rev. 2023 Jan 25;32(167):220141. doi: 10.1183/16000617.0141-2022. Print 2023 Mar 31. Eur Respir Rev. 2023. PMID: 36697209 Free PMC article. Review.
-
Penetration of pefloxacin into bronchial secretions.Antimicrob Agents Chemother. 1989 Mar;33(3):391-3. doi: 10.1128/AAC.33.3.391. Antimicrob Agents Chemother. 1989. PMID: 2729932 Free PMC article.
-
Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344].BMC Pulm Med. 2004 Dec 6;4:13. doi: 10.1186/1471-2466-4-13. BMC Pulm Med. 2004. PMID: 15581425 Free PMC article. Clinical Trial.
-
Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.Int J Chron Obstruct Pulmon Dis. 2015 Oct 28;10:2319-25. doi: 10.2147/COPD.S87091. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26604731 Free PMC article. Clinical Trial.
-
Additive effect of continuous low dose ofloxacin on erythromycin therapy for sinobronchial syndrome.Drugs. 1995;49 Suppl 2:409-11. doi: 10.2165/00003495-199500492-00116. Drugs. 1995. PMID: 8549380 Clinical Trial. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical